ClinicalTrials.gg
Not yet recruitingNCT07565545PIERCEUpdated Nov 16, 2026

Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes

An observational study in Sacro Iliac Joint Pain, Sacro-iliac Joints and Sacroiliac Disorder, sponsored by SI-BONE, Inc.. Not yet recruiting. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by SI-BONE, Inc. · Observational

How we know

Updated Nov 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
21 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate outcomes in patients treated with iFuse INTRA Ti for chronic SI joint pain.

Read the detailed description

PIERCE is a prospective, multicenter, post-market observational study evaluating the safety, performance, and efficacy of iFuse INTRA Ti.

02

Conditions studied

  • Sacro Iliac Joint Pain
  • Sacro-iliac Joints
  • Sacroiliac Disorder
  • Sacroiliac Joint Dysfunction
  • Sacroiliac Joint Disruption
  • Degenerative Sacroiliitis

Keywords

  • sacroiliac fusion
  • SI-BONE
  • INTRA Ti
03

In context

Arthralgia

277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.

This study's planned enrollment of 120 is close to the median of 114 across 50 observational studies indexed under Arthralgia.

Browse Arthralgia studies →

Lead sponsor

SI-BONE, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with sacroiliac joint (SIJ) dysfunction due to degenerative sacroiliitis or sacroiliac joint disruption for at least 6 months refractory to non-surgical care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 21 years.
  2. Patient has chronic lower back pain (≥6 months) to non-surgical care.
  3. Diagnosis of sacroiliac joint dysfunction (degenerative sacroiliitis or SIJ disruption) and scheduled to be treated with INTRA Ti.
  4. Patient has SIJ pain of at least 5 on a 0-10 numeric rating scale (NRS) prior to procedure.
  5. Participant has signed study-specific form.

Exclusion criteria

Exclusion Criteria:

  1. 4 or 5.
  2. Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture.
  3. Other known sacroiliac pathology such as: inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy), tumor, infection, acute fracture.
  4. Current diagnosis of cluneal neuralgia.
  5. Previous SIJ implant placement, including allograft, on the treated (index) side.
  6. Anatomic anomalies/defects that would preclude safe and/or biomechanically acceptable device placement.
  7. History of recent (\<1 year) major trauma to pelvis.
  8. Previously diagnosed or suspected severe osteoporosis (defined as prior T-score \< -2.5 or history of osteoporotic fracture).
  9. Chronic rheumatologic condition (e.g., rheumatoid arthritis).
  10. Current diagnosis of fibromyalgia.
  11. Known allergy to titanium or titanium alloys.
  12. Current local or systemic infection that raises the risk of surgery.
  13. Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
  14. Currently pregnant or planning pregnancy in the next 2 years (self-reported).
  15. Patient is a prisoner or a ward of the state.
  16. Known or suspected active drug or alcohol abuse, including opioids
  17. Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • SIJ Dysfunction treated with INTRA Ti

    Patients with sacroiliac joint (SIJ) dysfunction due to various causes refractory to non-surgical management.

    Device: iFuse INTRA Ti Implant System

Interventions

  • DeviceiFuse INTRA Ti Implant System

    FDA-cleared implant used for fusion of the sacroiliac joint (SIJ) for SIJ dysfunction, that is a direct result of SIJ disruption and degenerative sacroiliitis.

06

What researchers measure

Primary outcomes

  1. Composite endpoint of safety and performance

    The participant is considered a success if all the following criteria are met: * A ≥ 2 point improvement from baseline in SIJ pain on the target side. * Absence of device-related SAE. * Absence of SSI at index procedure.

    Time frame: 6 months.

Secondary outcomes

  1. Proportion of Participants with a Serious Adverse Event (SAE)

    Proportion of participants with a serious adverse event classified as probably or definitely related to the study device or procedure

    Time frame: 24 months

  2. Proportion of Participants with ≥1 Subsequent Surgical Intervention(s) (SSI)

    Proportion of participants undergoing one or more SSI related to the index procedure.

    Time frame: 24 months

  3. Proportion of Treated Sides with Radiographic Evidence of Loosening

    Proportion of treated sides showing signs of loosening of INTRA Ti, as evidenced by both radiolucent areas around implant plus bony reaction ("rind") near implant.

    Time frame: 24 months

  4. Proportion of Implants with Radiographic Evidence of Device Migration.

    Proportion of INTRA Ti implants that show evidence of device migration.

    Time frame: 24 months

  5. Proportion of Implants with Radiographic Evidence of Device Breakage.

    Proportion of INTRA Ti implants that show breakage.

    Time frame: 24 months

  6. Proportion of Participants with Radiographic Evidence of Fusion

    Bony apposition to the implant at 12 months as evaluated by pelvic CT

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There are currently no plans to share but IPD may be shared with qualified researchers upon reasonable request, subject to sponsor approval and data use agreements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

Of 21 observational studies under Arthralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 56. This study's planned 18 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Sep 2026 → Dec 2026, primary completion Mar 2028 → Jun 2028 and completion Sep 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartEst.
Dec 2026was Sep 2026
Primary completionEst.
Jun 2028was Mar 2028
CompletionEst.
Dec 2029was Sep 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Dec 2026
Nov 16, 2026
Primary completion
Mar 2028→Jun 2028
Nov 16, 2026
Study completion
Sep 2029→Dec 2029
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Sep 2026→Dec 2026
    Primary completion Mar 2028→Jun 2028
    Study completion Sep 2029→Dec 2029

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07565545
Lead sponsor
SI-BONE, Inc.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Director of Clinical Affairs
Contact
clinicalaffairs.@si-bone.com
408-207-0700
Stacie Tran, MPH
study director · SI-BONE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion